back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2019-03-25 Tx date 2019-03-15 |
$RQB
RavenQuest BioMed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$140,000
+175,000 vol $0.80 each |
175,000 | |
| Filed 2019-03-25 Tx date 2019-03-15 |
$RQB
RavenQuest BioMed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$210,000
+350,000 vol $0.60 each |
1,800,000 | |
| Filed 2018-10-10 Tx date 2018-10-09 |
$RQB
RavenQuest BioMed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-261,500
-250,000 vol $1.05 each |
1,450,000 | |
| Filed 2018-05-30 Tx date 2018-05-22 |
$RQB
RavenQuest BioMed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-191,317.50
-225,000 vol $0.85 each |
1,700,000 | |
| Filed 2018-05-30 Tx date 2018-05-18 |
$RQB
RavenQuest BioMed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-21,500
-25,000 vol $0.86 each |
1,925,000 | |
| Filed 2017-10-31 Tx date 2017-10-26 |
$RQB
RavenQuest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$20,000
+400,000 vol $0.05 each |
1,950,000 | |
| Filed 2017-10-31 Tx date 2017-10-26 |
$RQB
RavenQuest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-20,000
-400,000 vol $0.05 each |
0 | |
| Filed 2017-10-30 Tx date 2017-10-25 |
$RQB
RavenQuest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$312,500
+250,000 vol $1.25 each |
250,000 | |
| Filed 2017-10-30 Tx date 2017-09-06 |
$RQB
RavenQuest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-10-05 Tx date 2017-09-06 |
$RQB
RavenQuest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
400,000 | ||
| Filed 2017-09-29 Tx date 2017-09-28 |
$RVT
Ravenquest Biomed Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$165,000
+550,000 vol $0.30 each |
1,550,000 | |
| Filed 2017-09-08 Tx date 2017-09-06 |
$RVT
Ravencrest Resources Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,000,000 | ||
| Filed 2016-04-26 Tx date 2016-04-25 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$58,500
+150,000 vol $0.39 each |
3,693,804 | |
| Filed 2016-03-18 Tx date 2016-03-18 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+100,000 vol |
3,543,804 | |
| Filed 2016-03-04 Tx date 2016-01-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+200,000 vol |
500,000 | |
| Filed 2016-01-15 Tx date 2016-01-12 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-67,200
-140,000 vol $0.48 each |
3,443,804 | |
| Filed 2016-01-13 Tx date 2016-01-11 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-9,500
-20,000 vol $0.475 each |
3,623,804 | |
| Filed 2016-01-13 Tx date 2016-01-11 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-19,200
-40,000 vol $0.48 each |
3,583,804 | |
| Filed 2016-01-13 Tx date 2016-01-08 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,700
-10,000 vol $0.47 each |
3,667,804 | |
| Filed 2016-01-13 Tx date 2016-01-08 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-11,160
-24,000 vol $0.465 each |
3,643,804 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$221,045
+1,300,266 vol $0.17 each |
3,700,532 | |
| Filed 2016-01-08 Tx date 2016-01-07 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,592
-5,400 vol $0.48 each |
3,677,804 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+1,300,266 vol |
1,450,266 | |
| Filed 2016-01-08 Tx date 2015-12-22 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
54 - Exercise of warrants
|
$-221,045.22
-1,300,266 vol $0.17 each |
0 | |
| Filed 2016-01-08 Tx date 2016-01-05 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,490.72
-17,328 vol $0.49 each |
3,683,204 | |
| Filed 2015-11-25 Tx date 2015-01-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$99,000
+300,000 vol $0.33 each |
2,000,000 | |
| Filed 2015-11-25 Tx date 2015-01-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+150,000 vol |
150,000 | |
| Filed 2015-11-25 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-08-07 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2015
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-08-07 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.50 per share prior to September 22, 2015
00 - Opening Balance-Initial SEDI Report
|
650,000 | ||
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
+400,266 vol |
2,100,266 | |
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures mature April 23, 2018
16 - Acquisition or disposition under a prospectus exemption
|
+$153,000 vol |
$153,000 | |
| Filed 2015-04-28 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
16 - Acquisition or disposition under a prospectus exemption
|
+900,000 vol |
900,000 | |
| Filed 2015-04-28 Tx date 2015-04-23 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Warrants exercisable at $0.17 per share prior to April 23, 2020
16 - Acquisition or disposition under a prospectus exemption
|
+400,266 vol |
1,300,266 | |
| Filed 2015-04-28 Tx date 2014-11-10 |
$SL
Supreme Pharmaceuticals Inc. |
Bechtel, Chris
4 - Director of Issuer
Direct Ownership
|
Convertible Debentures mature April 23, 2018
00 - Opening Balance-Initial SEDI Report
|